|
||||||||||||||||
| HUM-MOLGEN -> Events -> Meetings and Conferences | ||||||||||||||||
| New Directions in Neurodegenerative Drug Discovery & Development | ||||||||||||||||
| April 25, 2001 | ||||||||||||||||
|
SMi conferences, The Hatton, Hatton Gardens, London 18th & 19th July 2001 Day One – Wednesday 18th July 2001 8.30 Registration & Coffee 9.00 Chairman's Opening Remarks Dr Amaud Ythier, Vice President, Neurology Research & Development, Serono International INTRODUCTION GREYING OF THE POPULATION 9.10 The impact of an elderly population on the market for neuroprotective agents Increased life expectancy and increased quality of life expectancy The cost to society of neurodegenerative disorders Market size for new neuroprotective agents Current therapies vs medical need Overview of the development pipeline for neurodegenerative disorders Dr Gavin Kilpatrick, Research Director, CeNeS DRUG DISCOVERY AND DEVELOPMENT QUENCHING INFLAMMATION IN THE AD BRAIN 9.40 Anti-inflammatory approaches for slowing the progression of Alzheimer’s disease The involvement of neuroinflammation in AD pathology Current molecular targets and approaches for drugs to block neuroinflammation Clinical experience to date with anti-inflammatory drugs The “vaccine” approach, can we convince microglia to be our friends? Other approaches to AD therapy: prospects for drug cocktails Slowing AD progression: social and pharmacoeconomic impact Dr Matt Sadler, Vice President, Research, Immune Network CHRONIC IN VIVO MODELS FOR PHARMACOLOGICAL TESTING 10.20 Application of genetically modified and/or chronic intoxication evoked neurodegenerative disease animal models Genetic rodent models for Alzheimer’s (AD), Parkinson’s (PD), Huntington’s (HD) Chronic low level exposure to toxins may lead to chronic neurodegeneration- Role of partial inhibition of mitochondrial electron chain in oxidative damage Possible therapeutic role of Heat Shock Proteins in neurodegenerative diseases Dr Rudolf Urbanics, Deputy Research & Development Director, Biorex 11.00 Morning Coffee PRECLINICAL PHARMACOLOGY OF RILUZOLE IN PARKINSON’S DISEASE 11.20 Case study: Riluzole Excitoxicity in Parkinson’s disease Mechanism of action of riluzole Effect of riluzole and primate models of Parkinson’s disease Dr Georg Andrees Bohme, Head, Neurophysiology, Neurodegenerative Disease Group, Aventis NOVEL TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH NERVE REGENERATION 12.00 NeotrofinTM: Promising developments in the treatment of Alzheimer’s The role of beta amyloids in the formation of plaques How NeotrofinTM effects the processing of the amyloid precursor protein Phase II Clinical trial results for the drug NeotrofinTM What is the development potential of NeotrofinTM Dr Scott Wieland, Vice President, Product Development & Regulatory Affairs, NeoTherapeutics 12.40 Networking Lunch HUMAN NEURAL STEM CELL TRANSPLANTATION 2.00 Developing a technology to deal with neurodegenerative disorder drug development Properties and advantages of stem cell transplantation in the CNS What is the therapeutic potential for stem cell lines? Preclinical evidence for therapeutic efficacy Possible mechanisms of action of stem cell grafts Dr Helen Hodges, Founder Member & Consultant, ReNeuron NMDA ANTAGONISTS AND NEURODEGENERATION 2.40 Well tolerated NMDA receptor antagonists in the treatment of neurodegenerative disease NMDA antagonists – efficacy in neurodegeneration NMDA antagonists - tolerability Pre-clinical differentiation of well-tolerated NMDA antagonists for the treatment of neurodegeneration Dr Michael Snape, Principal Scientist, Vernalis 3.20 Afternoon Tea NEXT GENERATION THERAPEUTICS NEXT GENERATION ACETYLCHOLINE INHIBITORS 3.40 Case study: Janssen What is the need for new treatments for Alzheimer's in the current market? What is the efficacy of Reminyl® and how was this measured? Mechanism of action of Reminyl® What are the future development plans for this drug? Dr Luc Truyen, Global Medical Leader for Reminyl, Janssen Research Foundation POTENTIAL THERAPEUTICS FOR MILD COGNITIVE IMPAIRMENT (MCI) 4.20 Alzheimer’s Disease (AD) and other Neurodegenerative Dementias The focus of existing therapeutics The use of functional imaging studies to study glutamate transmission Experiences at Cortex - AMPAKINE®CX516 in clinical studies Dr Vincent Simmon, President, Cortex Pharmaceuticals 5.00 Chairman’s Closing Remarks and Close of Day One 5.10 NETWORKING DRINKS RECEPTION Day Two – Thursday 19th July 2001 8.30 Re-registration and Coffee 9.00 Chairman's Opening Remarks Dr Peter Mathisen, Head, Cell Models, CNS Research, Aventis NEW TARGETS IN NEURODEGENERATIVE DISEASE NOVEL TARGETS FOR NEURODEGENERATIVE DISORDER TREATMENTS 9.10 Dr Peter Mathisen, Head, Cell Models, CNS Research, Aventis TRANSGENIC ANIMAL MODELS 9.40 An overview of animal models in Alzheimer’s Disease (AD) What is the impact of gene disruption and transgenic technology in neurodegenerative research Amyloid precursor protein and presenilin knockouts Transgenes linked to familial early onset AD Development of new strains relevant to Alzheimer's Disease Conditional transgenics Dr Guy Seabrook, Senior Research Fellow, Merck Sharp & Dohme Research Laboratories CELL THERAPY FOR PARKINSON'S DISEASE 10.20 Regional brain replacement of dopamine Current dopaminergic based therapy for Parkinson’s based on: -Effectiveness -Side effects What is Spheramine and how does it work? What are the Phase I/II results for Spheramine? Describing the potential of cell therapy as a treatment for Parkinson’s Dr Louis Bucalo, President & CEO, Titan Pharmaceuticals 11.00 Morning Coffee TARGETING NEURODEGENERATIVE DISEASES 11.20 Ion channels in the CNS and their role for neurodegeneration Which mechanisms are important for neuronal function under physiological conditions? What changes during neurodegenerative diseases? Where can ion channel modulators be useful to fight neurodegeneration? Dr Thomas Weiser, Senior Scientist, Department of CNS Research, Boehringer Inglehiem NOVEL THERAPIES FOR ALZHEIMER'S 12.00 Functional g-Secretase inhibitors reduce beta-amyloid peptide levels in the brain The implication of the beta amyloid peptide (Aß) as causative in Alzheimer's disease (AD) How is the Aß peptide formed Reducing Aß production by functionally inhibiting g-secretase both in cell and animal models of AD. The in vivo and in vitro effects of these molecules The potential usefulness of these molecules in the treatment of AD Dr Patrick May, Senior Research Scientist, Alzheimer’s Disease Action Group, Eli Lilly 12.40 Networking Lunch NEURODEGENERATION INHIBITION AND REGENERATION 2.00 Strategies in the CNS Targeting anti-apoptotic mechanisms in progressive neurodegenerative disorders like Parkinson’s, Alzheimer’s and Huntington’s disease Small molecule approaches to: - mitochondrial apoptosis inhibition - signal transduction apoptosis inhibition - caspase inhibition Regenerative strategies in post-apoptotic neurodegenerative conditions - stem cell transplantation - embryonic neuronal transplantation Gene therapy in neurodegenerative models at Aegera Therapeutics - evidence from IAP transgenic models - NAIP and XIAP in adeno/adeno-associated viral vectors in apoptotic disorders of the CNS and eye Dr John Gillard, Chief Scientific Officer, Aegera TARGETING INTRACELLULAR MESSENGERS 2.40 The development of CEP-1347 for the treatment of Alzheimer's and Parkinson’s What is the role of the MLK's and the Stress Activated Protein Kinase Pathway in neuronal cell death What is the preclinical rationale for utility in neurodegenerative disease What is the clinical potential of this novel mechanism and impact on disease Dr Jeffry Vaught, President, Research & Development Division, Cephalon 3.20 Afternoon Tea 3.40 SPEAKER PANEL A unique interactive session to discuss the development of themes throughout the conference, along with the perspectives throughout the industry. If you would like to participate on this panel or have a question you would like to be asked, please contact me on tel: +44 (0)20 78276788, fax: +44(0)20 78276789, e mail: lmaher@smi-online.co.uk 4.20 Chairman’s Closing Remarks and Close of Conference |
||||||||||||||||
| Organized by: | Louise Maher | |||||||||||||||
| Invited Speakers: | A unique opportunity to learn from leading industry experts including: Dr Georg Andrees Bohme, Head, Neurophysiology, Neurodegenerative Disease Group, Aventis Dr Luc Truyen, Global Medical Leader for Reminyl, Janssen Research Foundation Dr Peter Mathisen, Head, Cell Models, CNS Research, Aventis Dr Pierre Pellier, Head, CNS Therapeutics, GlaxoSmithkline Dr Guy Seabrook, Senior Research Fellow, Merck Sharp & Dohme Research Laboratories Dr Patrick May, Senior Research Scientist, Alzheimer’s Disease Action Group, Eli Lilly Dr Thomas Weiser, Senior Scientist, Department of CNS Research, Boehringer Inglehiem Dr Matt Sadler, Vice President, Research, Immune Network Dr John Gillard, Chief Scientific Officer, Aegera Dr Michael Snape, Principal Scientist, Vernalis Dr Louis Bucalo, President & Chief Executive Officer, Titan Pharmaceuticals Dr Vincent Simmon, President, Cortex Pharmaceuticals Dr Helen Hodges, Founder Member & Consultant, ReNeuron Dr Jeffry Vaught, President, Research & Development Division, Cephalon Dr Rudolf Urbanics, Deputy Research & Development Director, Biorex Dr Scott Wieland, Vice President, Product Development & Regulatory Affairs, NeoTherapeutics Dr Gavin Kilpatrick, Research Director, CeNeS Chaired by Dr Amaud Ythier, Vice President, Neurology Research & Development, Serono International Dr Peter Mathisen, Head, Cell Models, CNS Research, Aventis |
|||||||||||||||
| Deadline for Abstracts: | No abstracts required | |||||||||||||||
| Registration: | £1099 + VAT | |||||||||||||||
| E-mail: | customer_services@smi-online.co.uk | |||||||||||||||
| Posted by: | Louise Maher | |||||||||||||||
| Host: | 213.38.112.46 | |||||||||||||||
|
||||||||||||||||
|
Generated by meetings and positions 5.0 by Kai Garlipp |
||||||||||||||||